000 01248 a2200337 4500
005 20250514234228.0
264 0 _c20050815
008 200508s 0 0 eng d
022 _a1468-2044
024 7 _a10.1136/adc.2004.069948
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aFeltes, T F
245 0 0 _aPalivizumab prophylaxis in haemodynamically significant congenital heart disease.
_h[electronic resource]
260 _bArchives of disease in childhood
_cAug 2005
300 _a875-7; author reply 875-7 p.
_bdigital
500 _aPublication Type: Comment; Letter
650 0 4 _aAntibodies, Monoclonal
_xtherapeutic use
650 0 4 _aAntibodies, Monoclonal, Humanized
650 0 4 _aAntiviral Agents
_xtherapeutic use
650 0 4 _aChild, Preschool
650 0 4 _aData Interpretation, Statistical
650 0 4 _aHeart Defects, Congenital
_xcomplications
650 0 4 _aHospitalization
650 0 4 _aHumans
650 0 4 _aInfant
650 0 4 _aPalivizumab
650 0 4 _aVirus Diseases
_xprevention & control
700 1 _aSimoes, E
773 0 _tArchives of disease in childhood
_gvol. 90
_gno. 8
_gp. 875-7; author reply 875-7
856 4 0 _uhttps://doi.org/10.1136/adc.2004.069948
_zAvailable from publisher's website
999 _c15694712
_d15694712